Weill Cornell Sandra & Edward Meyer Cancer Center | OncLive

Weill Cornell Sandra & Edward Meyer Cancer Center

Latest from Weill Cornell Sandra & Edward Meyer Cancer Center


FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

October 01, 2020

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

x